Resources from the same session
LBA3 - Patritumab deruxtecan (HER3-DXd) in early-stage HR+/HER2- breast cancer: final results of the SOLTI TOT-HER3 window of opportunity trial
Presenter: Aleix Prat
Session: Proffered Paper session 1
Resources:
Abstract
Slides
Webcast
162O - Primary analysis from DS8201-A-U105: A 2-part, open label, phase 1b trial assessing trastuzumab deruxtecan (T-DXd) with nivolumab (nivo) in patients (pts) with HER2-expressing advanced breast cancer
Presenter: Erika Hamilton
Session: Proffered Paper session 1
Resources:
Abstract
Slides
Webcast
Invited Discussant LBA3 and 162O
Presenter: Rebecca Dent
Session: Proffered Paper session 1
Resources:
Slides
Webcast
163O - Patient-reported outcomes (PROs) from DESTINY-Breast03, a randomized phase 3 study of trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (MBC)
Presenter: Giuseppe Curigliano
Session: Proffered Paper session 1
Resources:
Abstract
Slides
Webcast
164O - Health-Related Quality of Life (HRQoL) With Pembrolizumab (pembro) + Chemotherapy (chemo) vs Placebo (pbo) + Chemo as 1L Treatment for Advanced Triple-Negative Breast Cancer (TNBC): Results From KEYNOTE-355
Presenter: David Cescon
Session: Proffered Paper session 1
Resources:
Abstract
Slides
Webcast
Q&A and discussion
Presenter: All Speakers
Session: Proffered Paper session 1
Resources:
Webcast